Pharmaceutical marketing is still taking its first steps towards digital strategies. The high level of regulation in the sector leaves managers hesitant when it comes to investing in a digital strategy.
In fact, the first legislation on the subject of advertising in the pharmaceutical sector dates back to the 1970s (see here the Consolidat and Comment Legislation on the Advertising of Micines ) – and, of course, no regulation directly addresses the issue of disseminating information via the internet.
However, RDC-96, from 2008 , clarifies several aspects french email list 13 million contact leads about drug advertising, mainly regarding “indirect advertising”. Although there is no updat and specific legislation on digital communication, it is possible to follow the current regulations to develop a marketing strategy for the pharmaceutical sector.
In a way, some aspects of digital marketing can be consider indirect advertising, since they address solutions link to a product or service. However, it is in addition to creating dashboards possible to create content and develop a pharmaceutical marketing strategy in an informative and clear manner, without suffering regulatory penalties, both for prescription and non-prescription drugs. Here’s how:
Indirect Advertising
The legislation classifies as “indirect advertising” all communication materials that do not directly mention the name of the products, but show brands, symbols and designations that allow the consumer to identify what it is – this also applies to the mention of specific health treatments, even if the name of the micine is not mention.
This type of content is prohibit by the Consumer Protection Code itself – which requires that all advertising be broadcast in a way that the consumer can clearly identify that the content is an advertising piece.
Publishing content about diseases on the company’s institutional website
The legislation classifies explanatory content about pathologies philippines numbers as valid – again, without this content presenting any type of brand, symbol or designation of the company’s products. The manufacturer also cannot send messages, even to a small list of consumers, informing about the arrival of a new treatment, among other topics.
Another aspect that is also permitt by law is the institutional disclosure of the company, for example, information that comments on the company’s research into the treatment of diseases. However, the company cannot mention any product or substance. In this case, the content would be consider as propaganda, and the advertisement must comply with the law.